These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 17667631)

  • 1. Sjögren keratoconjunctivitis sicca treated with rituximab.
    Zapata LF; Agudelo LM; Paulo JD; Pineda R
    Cornea; 2007 Aug; 26(7):886-7. PubMed ID: 17667631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients.
    Lee HK; Ryu IH; Seo KY; Hong S; Kim HC; Kim EK
    Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
    Pflugfelder SC; Maskin SL; Anderson B; Chodosh J; Holland EJ; De Paiva CS; Bartels SP; Micuda T; Proskin HM; Vogel R
    Am J Ophthalmol; 2004 Sep; 138(3):444-57. PubMed ID: 15364229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
    El Tal AK; Posner MR; Spigelman Z; Ahmed AR
    J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Delayed response to rituximab of cold agglutinin haemolytic disease].
    Calvo-Villas JM; Cuesta Tovar J; Carreter de Granda E; Sicilia Guillén F
    An Med Interna; 2006 May; 23(5):224-8. PubMed ID: 16817700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy in primary Sjögren's syndrome.
    Alcântara C; Gomes MJ; Ferreira C
    Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in severe pemphigus.
    Schmidt E; Goebeler M; Zillikens D
    Ann N Y Acad Sci; 2009 Sep; 1173():683-91. PubMed ID: 19758216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
    Kong HH; Prose NS; Ware RE; Hall RP
    Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
    Cianchini G; Corona R; Frezzolini A; Ruffelli M; Didona B; Puddu P
    Arch Dermatol; 2007 Aug; 143(8):1033-8. PubMed ID: 17709662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.
    Mease PJ
    J Rheumatol; 2008 Jul; 35(7):1245-55. PubMed ID: 18609733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
    Roll P; Dörner T; Tony HP
    Arthritis Rheum; 2008 Jun; 58(6):1566-75. PubMed ID: 18512772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
    Faurschou A; Gniadecki R
    Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE.
    Abdwani R; Mani R
    Lupus; 2009 Apr; 18(5):460-4. PubMed ID: 19318402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for the treatment of post-bone marrow transplantation refractory hemolytic anemia in a child with Omenn's syndrome.
    Silvana B; Antonella LM; Basilia P; Trombetta D; Saija A; Salpietro C
    Pediatr Transplant; 2007 Aug; 11(5):552-6. PubMed ID: 17631027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab.
    Taverna JA; Lerner A; Bhawan J; Demierre MF
    J Drugs Dermatol; 2007 Jul; 6(7):731-2. PubMed ID: 17763598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lacrimal punctum occlusion in the treatment of severe keratoconjunctivitis Sicca caused by Sjögren syndrome: a uniocular evaluation.
    Mansour K; Leonhardt CJ; Kalk WW; Bootsma H; Bruin KJ; Blanksma LJ;
    Cornea; 2007 Feb; 26(2):147-50. PubMed ID: 17251802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effect of topical fibronectin in patients with keratoconjunctivitis sicca of Sjögren's syndrome.
    Kono I; Matsumoto Y; Kono K; Ishibashi Y; Narushima K; Kabashima T; Yamane K; Sakurai T; Kashiwagi H
    J Rheumatol; 1985 Jun; 12(3):487-9. PubMed ID: 4045849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for myasthenia gravis: three case reports and review of the literature.
    Stieglbauer K; Topakian R; Schäffer V; Aichner FT
    J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.